In a comparison of vaccinated vs unvaccinated young adults, oral HPV infection prevalence was found to be substantially lower in persons 18 to 33 years who received at least 1 vaccine-dose during the study years.
Axalimogene filolisbac, an intravenous vaccine currently in clinical trials, could prevent often-fatal cervical cancer relapse.
Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.
ASCO offers global recommendations for HPV vaccination tailored to structural resource levels of regions.
Self-persuasion is more effective than external persuasion for motivating low-income parents to vaccinate their children against HPV.
The top reasons for not initiating HPV vaccination are necessity, safety, and knowledge, rather than a lack of discussions on sexuality.
A comparison of administering the influenza vaccine concurrently with chemotherapy with that of administration within the cytopenic period during 3-week chemotherapy cycles determined which schedule was the optimal timing for vaccination administration in this group.
A recent study examined the current economic burden attributable to vaccine-preventable diseases among U.S. adults.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
Oncologists should raise awareness of HPV-related cancers and role of vaccinations
